fbpx

Safilo Announces New Licensing Agreement for Moschino and Love Moschino

Padua – Safilo Group announces a new licensing agreement for the design, manufacturing and worldwide distribution of the Moschino and Love Moschino collections of optical frames and sunglasses. The agreement will run for eight years starting from January 2018 until December 31, 2025, with an optional extension for a further eight years.

The Moschino and Love Moschino Eyewear collections will be distributed worldwide in quality optical stores, department stores and in all Moschino Boutiques.

Click HERE to read full press release.

Johnson & Johnson Acquires Abbott Medical Optics

Johnson & Johnson today announced a definitive agreement to acquire Abbott Medical Optics, a wholly-owned subsidiary of Abbott Laboratories, for $4.325 billion in cash. AMO reported sales of $1.1 billion for 2015. The acquisition will include ophthalmic products in three business segments: cataract surgery, laser refractive surgery and consumer eye health.

“Eye health is one of the largest, fastest growing and most underserved segments in health care today,” said Ashley McEvoy, Company Group Chairman, responsible for Johnson & Johnson’s Vision Care Companies. “With the acquisition of Abbott Medical Optics’ strong and differentiated surgical ophthalmic portfolio, coupled with our world-leading ACUVUE® contact lens business, we will become a more broad-based leader in vision care.  Importantly, with this acquisition we will enter cataract surgery – one of the most commonly performed surgeries and the number one cause of preventable blindness.”

AMO is a global leader in ophthalmic surgery and is known for world-class intraocular lenses used in cataract surgery. The World Health Organization estimates that approximately 20 million people are blind from age-related cataracts and that there are at least 100 million eyes with compromised visual acuity caused by cataracts. These numbers are steadily rising due to population growth and increasing life expectancy.

In addition to the cataract business, AMO has advanced laser vision (LASIK) technologies designed to enhance surgeon productivity and correct near sightedness, far sightedness and astigmatism.  The acquisition also includes AMO’s consumer eye health products – over-the-counter drops for dry eye, as well as multipurpose solutions and hydrogen peroxide cleaning systems for patients who wear contact lenses.

The transaction is expected to close in the first quarter of 2017 and would be modestly accretive immediately to adjusted earnings per share.  The closing is subject to antitrust clearance and other customary closing conditions. Following the expected closing, sales will be reported in the Medical Devices segment as a separate platform within Vision Care.

Documentary on Vision is First Film Adapted for the Colour-Blind

Sight: The Story of Vision, a documentary on the science, medicine and technology of human vision, narrated by Sir Elton John, is the first film to be broadcast with a colour correction that is adapted for the vision of people with colour blindness. Like Closed Captioning (CC) for the hearing impaired, and Video Description (VD) for low vision and the blind, the colour blind accessible correction (CA) helps those with limited red-green colour sensitivity better see differences between colours they normally struggle to distinguish.

“A few weeks ago, I tried a pair of EnChroma glasses designed to help with colour blindness,” said Kris Koenig, the film’s writer and director. “When I looked through the glasses, greens and reds became more vibrant without degrading the rest of the visible spectrum. It got me thinking about applying colour correction for the colour blind to the film, like EnChroma does with its glasses.”

Koenig worked with EnChroma President and CEO, Andrew Schmeder, to develop a colour calibration method to approximate the effect of EnChroma glasses. Steve Challot, the film’s editor, used the calibration data to implement the correction, which isolates and enhances colour along the red-green axis of colour space. The result improves the viewing experience for up to 80% of people with red-green colour blindness, depending on type and severity. An estimated 300 million people worldwide have some form of colour vision deficiency.

Full Press Release available HERE.

RightEye Developing Eye-tracking Tests for Autism and Parkinson’s Disease

RightEye LLC, a health technology company using eye tracking to revolutionize vision performance and patient care, announced today that it has acquired the exclusive rights to two internationally recognized eye movement tests that help doctors more accurately and objectively identify early stages of autism in children 12 to 40 months old, and detect Parkinson’s disease in patients of all ages. The tests, which are based on extensive clinical studies, help identify both disorders earlier and more accurately, which can lead to earlier and more appropriate intervention.

“RightEye has consistently pioneered the use of eye-tracking technology to help solve some of health care’s greatest challenges,” said Barbara Barclay, president of RightEye. “Acquiring these tests has implications that reach far beyond our business — as our eye movement technology platform will now enable parents, patients and providers to get reliable and objective answers they need, when they need them, anywhere in the world at a lower cost.”

RightEye’s newly acquired test to identify autism is the GeoPref Autism Test, developed by Dr. Karen Pierce, which uses eye-tracking technology to compare the amount of time children spend looking at videos of people with the amount of time they spend looking at videos of geometric shapes. According to peer-reviewed research, children with healthy brains will spend more time looking at the videos containing faces. This new test results in identifying in one in five cases, and identifies children for further testing in nearly half of cases, allowing for early therapy intervention, which can have a profound impact on outcomes. The American Pediatric Association recommends intervention before age 3, yet often children are not diagnosed until later.

“In developing the GeoPref Autism Test, my goal was to make it easier, faster and more affordable to identify toddlers at risk for autism,” said Dr. Karen Pierce, the developer of the test and a leading researcher in understanding autism. “By partnering with RightEye, I knew that I would be able to make my test more accessible to health care providers and parents of young children seeking answers about an often-misunderstood and late-diagnosed disorder.”

RightEye’s POM (Parkinson’s and Other Movement) Disorders Test identifies Parkinson’s and other rare movement disorders, including Huntington’s disease and Essential Tremor. Developed by a neurologist and researchers from Virginia Commonwealth University’s Parkinson’s and Movement Disorders Center and the U.S. Department of Veterans Affairs, the test accurately identifies and assesses patterns of eye movement that are affected in patients with movement disorders. The test, which offers more accuracy than traditional diagnostic methods, takes only five minutes and has a dramatically lower cost than the extensive, costly PET scans and MRIs usually required for diagnosis.

Carl Zeiss Meditec Appoints Global Sales Leader for Ophthalmic Devices

DUBLIN, CA USA / JENA, GERMANY- In August 2016, Carl Zeiss Meditec consolidated its ophthalmic diagnostic and surgical business into a single Strategic Business Unit (SBU) Global Ophthalmic Devices headed by Jim Mazzo. ZEISS announces that the Global Sales organization for the newly consolidated SBU, comprised of Surgical Ophthalmology, Ophthalmic Diagnostics and Refractive Lasers, will be led by Andrew Ihan Chang.

Prior to joining ZEISS, Chang was General Manager and Senior Vice President for Bausch + Lomb Surgical where he led the sales, marketing, operations and business development for the US. Previously at Optimedica Corporation / Abbott Medical Optics, Inc., Chang led the marketing and launch of new laser systems and new indications globally. At ISTA Pharmaceutical / Bausch + Lomb, Chang held various marketing, sales and product development roles and led the market introductions of ophthalmic pharmaceuticals.

For full press release, click HERE.

Featured Posts

AAO American Academy of Optometry logo 2026

Academy 2026 Anaheim Showcases Research, Innovation and Leaders Shaping the Future of Eye Care

Academy 2026 Anaheim showcased major research, innovation and leadership in optometry, featuring landmark studies, new Fellows and advances shaping the future of eye care.

Learn More
Zeiss Myopia Summit 2026-EN

ZEISS Myopia Innovation Summit Turns Evidence into Action in Vancouver

ZEISS gathered eye care professionals in Vancouver for the Myopia Innovation Summit, introducing MyoActive and showcasing evidence based strategies for myopia management.

Read more
Optometry Practice Succession Planning

Succession Made Simple

Learn how early optometry practice succession planning can improve practice value, reduce owner dependence, protect tax eligibility, and create a smoother transition.

Read more
CIBC logo 2026

CIBC Commercial Banking Steps Into Canadian Optometry

CIBC Commercial Banking is stepping into Canadian optometry through a new collaboration with Eye Care Business Canada, debuting with a webinar on buying an optometric practice.

Read more
AAO 2026 Lumenis at Brasas_8 and Lumenis logo oct 2026

Lumenis Launches New Field Guide to Address Hidden Causes of Post‑Surgical Dissatisfaction at AAO 2026

Lumenis unveiled a new perioperative ocular surface care field guide at AAO 2026, offering surgeons practical tools to identify hidden causes of post surgical dissatisfaction.

Read more
AAO American Academy of Optometry logo 2026

Academy 2026 Anaheim Showcases Research, Innovation and Leaders Shaping the Future of Eye Care

Academy 2026 Anaheim showcased major research, innovation and leadership in optometry, featuring landmark studies, new Fellows and advances shaping the future of eye care.

Learn More
Zeiss Myopia Summit 2026-EN

ZEISS Myopia Innovation Summit Turns Evidence into Action in Vancouver

ZEISS gathered eye care professionals in Vancouver for the Myopia Innovation Summit, introducing MyoActive and showcasing evidence based strategies for myopia management.

Read More
Optometry Practice Succession Planning

Succession Made Simple

Learn how early optometry practice succession planning can improve practice value, reduce owner dependence, protect tax eligibility, and create a smoother transition.

Read More
CIBC logo 2026

CIBC Commercial Banking Steps Into Canadian Optometry

CIBC Commercial Banking is stepping into Canadian optometry through a new collaboration with Eye Care Business Canada, debuting with a webinar on buying an optometric practice.

Read More
AAO 2026 Lumenis at Brasas_8 and Lumenis logo oct 2026

Lumenis Launches New Field Guide to Address Hidden Causes of Post‑Surgical Dissatisfaction at AAO 2026

Lumenis unveiled a new perioperative ocular surface care field guide at AAO 2026, offering surgeons practical tools to identify hidden causes of post surgical dissatisfaction.

Read More
AAO American Academy of Optometry logo 2026

Academy 2026 Anaheim Showcases Research, Innovation and Leaders Shaping the Future of Eye Care

Academy 2026 Anaheim showcased major research, innovation and leadership in optometry, featuring landmark studies, new Fellows and advances shaping the future of eye care.

Learn More
Zeiss Myopia Summit 2026-EN

ZEISS Myopia Innovation Summit Turns Evidence into Action in Vancouver

ZEISS gathered eye care professionals in Vancouver for the Myopia Innovation Summit, introducing MyoActive and showcasing evidence based strategies for myopia management.

Read more
Optometry Practice Succession Planning

Succession Made Simple

Learn how early optometry practice succession planning can improve practice value, reduce owner dependence, protect tax eligibility, and create a smoother transition.

Read more
CIBC logo 2026

CIBC Commercial Banking Steps Into Canadian Optometry

CIBC Commercial Banking is stepping into Canadian optometry through a new collaboration with Eye Care Business Canada, debuting with a webinar on buying an optometric practice.

Read more
AAO 2026 Lumenis at Brasas_8 and Lumenis logo oct 2026

Lumenis Launches New Field Guide to Address Hidden Causes of Post‑Surgical Dissatisfaction at AAO 2026

Lumenis unveiled a new perioperative ocular surface care field guide at AAO 2026, offering surgeons practical tools to identify hidden causes of post surgical dissatisfaction.

Read more
AAO American Academy of Optometry logo 2026

Academy 2026 Anaheim Showcases Research, Innovation and Leaders Shaping the Future of Eye Care

Academy 2026 Anaheim showcased major research, innovation and leadership in optometry, featuring landmark studies, new Fellows and advances shaping the future of eye care.

Learn More
Zeiss Myopia Summit 2026-EN

ZEISS Myopia Innovation Summit Turns Evidence into Action in Vancouver

ZEISS gathered eye care professionals in Vancouver for the Myopia Innovation Summit, introducing MyoActive and showcasing evidence based strategies for myopia management.

Read more
Optometry Practice Succession Planning

Succession Made Simple

Learn how early optometry practice succession planning can improve practice value, reduce owner dependence, protect tax eligibility, and create a smoother transition.

Read more
CIBC logo 2026

CIBC Commercial Banking Steps Into Canadian Optometry

CIBC Commercial Banking is stepping into Canadian optometry through a new collaboration with Eye Care Business Canada, debuting with a webinar on buying an optometric practice.

Read more
AAO 2026 Lumenis at Brasas_8 and Lumenis logo oct 2026

Lumenis Launches New Field Guide to Address Hidden Causes of Post‑Surgical Dissatisfaction at AAO 2026

Lumenis unveiled a new perioperative ocular surface care field guide at AAO 2026, offering surgeons practical tools to identify hidden causes of post surgical dissatisfaction.

Read more